CardioMEMS lands $22 million VC round: Wireless sensing and communications developer CardioMEMS closes round of financing to bankroll its heart failure clinical trial.
UPDATE: MassDevice’s earnings roundup
Here’s a rundown of how medical device companies have fared so far as the second-quarter earnings season winds down (updated August 25, 2009):
Medtronic:
The Minneapolis-based medical device monolith’s bottom line takes a $360 million hit, pushing net earnings down 38.5 percent, as it pays out $444 million to settle a patent infringement suit with arch-rival Abbott Labs. Read More
Career Sampler: Open jobs in the medical device industry
By popular demand, MassDevice presents a sampling of 10 of the hundreds of open positions in the medical device industry at employers across the country. No matter your expertise or specialty, the perfect medtech job is out there waiting!
To inquire about listing an opening at your company on MassDevice.com, please email info@massdevice.com.
MedTech Monday: Are IV bags the next fashion statement?
Turn your post-op recovery into a fashion statement: With designer Olivier Trillon’s concepts, you can choose between an Yves Saint Laurent or Chanel IV bag for your post-op morphine drip.
Weekly Wireless Roundup: The Bluetooth stethoscope
3M unveils $500 Bluetooth-enabled stethoscope: The conglomerate unveiled the Littmann 3200 stethoscope with a built-in Bluetooth radio that aims to better enable physicians to detect heart murmurs and other afflictions.
MedTech Monday: Embeda is for chronic pain, not crushing and snorting
Embeda is for chronic pain, not crushing and snorting: Newly approved Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules from King Pharmaceuticals Inc. ingeniously combines an opioid agonist (morphine) with an inner core of opioid antagonist (naltrexone). The naltrexone part of the capsule is sequestered, so it passes through the body with no intended clinical effect. But if any of you out there are thinking of crushing the capsule to enliven a slow night, please beware: The naltrexone will mix with morphine and give you an opioid withdrawal like you’ve never seen before.
Weekly Wireless Roundup: Cracking the vault
Connecting devices to Microsoft’s HealthVault: Mobihealthnews recently caught up with HealthVault’s senior global strategist George Scriban to discuss how the Microsoft unit fits into the wireless health discussion. Can mobile application developers sync their apps directly to HealthVault? Will Windows Mobile create apps that integrate to HealthVault? How does a medical device maker enable its users to send information to HealthVault?
Career Sampler: Open jobs in the medical device industry
By popular demand, MassDevice presents a sampling of some of the hundreds of open positions in the medical device industry at employers across the country. No matter your expertise or specialty, the perfect medtech job is out there waiting!
To inquire about listing an opening at your company on MassDevice.com, please email info@massdevice.com.
- Software Developer, Boston Scientific (St. Paul, Minn.) Read More
Is the life science IPO in recovery?
A Nashville-based electronic medical records provider drew flocks of investors to its initial public offering today, breathing some much-needed life into the moribund life science IPO market that’s been largely stalled since the economic downturn began last year.
Emdeon Inc.‘s stock opened at at $17.75 per share August 12, up 14.5 percent from yesterday’s IPO price of $15.50, the Wall Street Journal reported, as investors bagged 23.7 million shares — 2 million more than expected — at the high end of the expected range set by underwriters Morgan Stanley, Goldman Sachs Group Inc., UBS AG and Barclays PLC.
The offering pulled in about $367 million.
MedTech Monday: Philips bids on ultrasound-guided gene therapy
Philips bids on ultrasound-guided gene therapy: Delivering DNA sequences to cells for gene therapy is already being investigated, with the current approaches relying on viruses and smart nanoparticles as vectors for gene transfer. But Philips and GlyGenix Therapeutics, out of Woodbridge, Conn., plan on taking another approach, hoping that the large molecules can be pushed to their destination using ultrasound. Specifically, the pre-clinical trials will study the technology, known as ultrasound-mediated plasmid DNA (pDNA) delivery, on Glycogen Storage Disease Type 1a (GSD-1a) that exhibits a defective G6Pase gene.
Weekly Wireless Roundup: A chat with Joseph Kvedar
Interview with the Center for Connected Health: Center for Connected Health founder and director Joseph Kvedar tells Mobihealthnews about the center’s various wireless health programs: “We have programs in a number of chronic illnesses; heart failure is our most advanced program. For diabetes we have an up and coming, growing program,” Kvedar says. “We have done a lot of interesting things with high blood pressure, both in terms of our use as a provider but also in terms of in the market place as an employee benefit. We have a program up and coming in activity monitoring and weight control.